Current B cell-directed therapies for multiple sclerosis impact multiple B cell functions. CD98hc enables B cell clonal expansion and antibody production. I probed the relative importance of autoantibody secretion vs. other B cell functions in MS and targeted CD98hc as a possible therapeutic strategy. I report that the loss of CD98hc function in B cells largely prevents autoantibody production while preserving antigen-presenting and T cell-directing capacities. Mice lacking CD98hc in B cells are protected from EAE; importantly this is overcome with autoantibody-containing plasma. Thus CD98hc blockade is a possible avenue to treat MS by inhibiting clonal expansion and autoantibody.
Introduction
Multiple sclerosis (MS) patients that do not respond well to interferon and other first-line disease-modifying therapies (DMT) have an urgent need for new immune treatments. Recent studies using a pan-CD20+ B cell-depleting antibody (Rituxan) show that immune therapies directed against B cells can be effective for multiple sclerosis, although additional autoimmunity and PML risk are current concerns (Berger and Koralnik, 2005; Hauser et al., 2008; Buttmann, 2010; Fontoura, 2010) . B cells are important in the pathogenesis of multiple sclerosis, but in their multiple roles may both contribute, and/or protect, from disease (Cross and Waubant, 2011; Mann et al., 2012) . Initially they direct helper T cell responses by presenting antigen (APC function), controlling Treg numbers, and guiding effector T cell differentiation (Ray et al., 2011; von Budingen et al., 2011; Ray et al., 2012) . Following clonal expansion, B cells differentiate into plasma cells, the major source of both protective and auto-antibodies. I previously described a protein, CD98 heavy chain (CD98hc) (Cantor and Ginsberg, 2012) , which controls clonal expansion of B cells and their subsequent differentiation to plasma cells (Cantor et al., 2009) . Genetic deletion of CD98hc blocks plasma cell formation, but maintains B cell numbers and preserves their ability to become activated and function as APC (Cantor et al., 2009 ). Thus I hypothesized that targeting CD98hc on B cells might selectively impair expansion-dependent B cell functions and delay or prevent experimental MS. Mice deficient for CD98hc on B cells showed significant protection from experimental autoimmune encephalomyelitis (EAE) induced with recombinant MOG (rMOG). Anti-MOG autoantibody levels were drastically reduced; however, B cell steady-state functions were preserved. Importantly, anti-MOG-containing mouse plasma could reconstitute disease in recipients lacking B cell CD98hc, supporting the importance of B cell autoantibody in EAE pathogenesis. Thus, I provide a new model to test the role of steady-state vs. clonally-expanded B cell functions in multiple sclerosis (MS), and reveal a new potential target for therapeutic blockade.
Methods

Mice and antigens
Slc3a2
f/f , CD19-Cre+ mice were generated as previously described (Feral et al., 2005; Cantor et al., 2009) . Littermate control Slc3a2 f/f mice were used whenever possible. OT-2 mice (Barnden et al., 1998) were purchased from Jackson Labs. All mice were housed and treated according to approved Institutional Animal Care and Use Committee (IACUC) guidelines. MOG 33-55 was purchased from Anaspec, and recombinant human MOG was a gift from Dr. Claude Bernard.
